Cipla Lines Up A Slate Of US Launches For FY23
As COVID-19 Antibody Cocktail Now Available In India
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.
